Herantis Pharma Oyj

HRTIS · HE · Healthcare / Biotechnology

1.27EUR+0.05 (+4.27%)

Price History

Full chart

Market Stats

Previous Close1.22

Open1.22

Day Range1.15 – 1.31

52-Week Range1.34 – 3.87

Volume45.58K

Market Cap37.58M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.27

Dividend Yield0.00%

Beta0.60

50-Day Avg1.55

200-Day Avg1.84

About

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Antti Vuolanto D.Sc. (Tech)
Employees14
HeadquartersBertel Jungin Aukio 1, Espoo, Finland, 02600, Finland
Websitehttps://herantis.com

Leadership

Dr. Antti Vuolanto D.Sc. (Tech)Chief Executive Officer · b. 1975
Ms. Tone KvaleChief Financial Officer · b. 1969
Dr. Henri J. Huttunen Ph.D.Chief Scientific Officer
Mr. Jani KoskinenHead of CMC
Dr. Juha-Matti Savola M.D., Ph.D.Chief Medical Officer
Dr. Charlotte Videbaek M.D.Clinical Consultant · b. 1962

Financials

Income Statement

Currency: EUR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	43.91	0	800	1.96K	25.29K	0	0	0	0	0	0	0	0	0
Growth (%)	-	-	-100.00%	-	+144.38%	+1193.66%	-100.00%	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	0	0	11.27M	27.09K	1.22M	1.20M	1.05M	927.71K	-	-	-	-	-
Gross Profit	-	43.91	0	800	-11.27M	-1.80K	-1.22M	-1.20M	-1.05M	-928.00K	-	-	-	-	-
Gross Margin	-	100.00%	-	100.00%	-576265.98%	-7.11%	-	-	-	-	-	-	-	-	-
Operating Expense	-	424.04K	752.00K	7.66M	4.90M	4.42M	1.02M	3.67M	6.11M	7.14M	-	-	-	-	-
Operating Income	-1.47M	-424.00K	-752.00K	-7.66M	-16.17M	-4.42M	-2.24M	-4.87M	-7.16M	-8.07M	-9.05M	-7.99M	154.37K	-5.03M	-6.39M
Operating Margin	-	-965611.48%	-	-957125.00%	-826905.37%	-17477.28%	-	-	-	-	-	-	-	-	-
EBITDA	-1.40M	-339.00K	-450.00K	-6.34M	-6.54M	-3.14M	-638.00K	-2.92M	-6.09M	-7.14M	6.92M	7.98M	831.44K	-4.93M	-6.39M
EBITDA Margin	-	-772033.71%	-	-793125.00%	-334475.70%	-12411.76%	-	-	-	-	-	-	-	-	-
Net Income	-1.45M	-394.00K	-781.00K	-8.36M	-16.05M	-4.42M	-2.17M	-4.18M	-8.01M	-9.15M	-23.58M	-9.32M	279.84K	-4.94M	-6.62M
Net Income Margin	-	-897289.91%	-	-1044500.00%	-820716.11%	-17494.40%	-	-	-	-	-	-	-	-	-
R&D	-	-	-	3.80M	14.05M	2.73M	2.33M	2.10M	4.93M	5.33M	6.20M	5.00M	2.70M	3.60M	-
R&D as % of Total Revenue	-	-	-	475000.00%	718772.38%	10785.28%	-	-	-	-	-	-	-	-	-
Interest Expense	9.52K	13.96K	28.23K	926.75K	84.24K	82.53K	309.24K	60.63K	868.80K	1.08M	63.03K	1.33M	551.60K	5.66K	13.75K
Interest Expense % of Total Revenue	-	31783.19%	-	115843.37%	4309.16%	326.31%	-	-	-	-	-	-	-	-	-

Balance Sheet

Currency: EUR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	670.13K	2.21M	2.64M	29.49M	14.09M	10.21M	11.57M	7.15M	11.07M	16.42M	6.92M	6.23M	6.75M	2.57M	2.67M
Total Liabilities	1.92M	2.21M	2.52M	7.77M	8.09M	8.63M	7.48M	7.24M	9.22M	8.83M	6.36M	6.29M	2.02M	2.81M	4.36M
Total Equity	-1.25M	-3.37K	120.00K	21.72M	6.00M	1.57M	4.09M	-89.29K	1.85M	7.59M	554.30K	-60.28K	4.73M	-243.00K	-1.69M
Cash	246.06K	9.17K	17.71K	2.42M	540.56K	782.19K	90.60K	719.11K	6.01M	12.34M	5.63M	5.04M	5.50M	635.00K	751.00K
Total Debt	1.25M	1.68M	1.85M	6.52M	7.72M	8.12M	6.57M	6.39M	7.21M	7.21M	4.69M	4.54M	34.82K	30.00K	3.45M
Net Debt	1.00M	1.67M	1.83M	4.10M	7.18M	7.34M	6.48M	5.67M	1.20M	-5.13M	-939.10K	-494.69K	-5.47M	-605.00K	2.70M

Cash Flow

Currency: EUR	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-533.42K	-224.21K	-4.36M	-7.40M	-3.04M	-2.60M	-3.73M	-5.96M	-8.56M	-9.93M	-8.94M	-4.64M	-6.54M	-6.10M
Investing Cash Flow	-1.77M	-842.70K	-14.62K	-6.15K	-71.34K	-32.96	7.17K	3.69K	3.69K	-1.05M	-210.13K	607.08K	-474.00K	-244.00K
Financing Cash Flow	2.07M	1.08M	15.78M	1.53M	395.92K	5.17M	508.62K	10.77M	14.88M	4.03M	8.56M	4.50M	2.15M	6.46M
Capital Expenditure	1.77K	842.70K	13.46K	6.15K	10.38K	0	0	0	0	0	0	3.7	0	6.10M
Free Cash Flow	-2.31K	-224.21K	-4.37M	-7.40M	-3.05M	-2.60M	-3.73M	-5.96M	-8.56M	-9.93M	-8.94M	-4.64M	-6.54M	-6.10M
FCF to OCF	0.43%	100.00%	100.31%	100.08%	100.34%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	99.97%

Earnings

Report Date	Mar 2, 2018	Aug 29, 2018	Feb 28, 2019	Aug 28, 2019	Feb 27, 2020	Aug 25, 2020	Mar 3, 2021	Aug 26, 2021	Mar 7, 2022	Aug 25, 2022	Mar 2, 2023
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-0.03	-0.36	-0.49	-0.55	-0.83	-0.59	-0.46	-0.77	-0.37	-0.46	-0.22
Surprise	-	-	-	-	-	-	-	-	-	-	-
Timing	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	-	Pre-market

Key Statistics & Ratios

Market Cap37.58M

Enterprise Value33.41M

Trailing P/E0.00

Forward P/E0.00

Price / Sales1025.84

Price / Book30.17

EPS-0.27

Book Value-0.03

Revenue (TTM)-135.00K

Gross Profit (TTM)-135.00K

EBITDA-7.99M

Profit Margin0.00%

Operating Margin4817.54%

Return on Equity-1415.14%

Return on Assets-88.85%

Shares Outstanding26.50M

Shares Float16.79M

Beta0.60

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

May 4, 20221737:1652